Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | Chief Business Officer | February 18, 2026 | February 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cullinan Therapeutics, Inc.
Report date February 18, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.44 · Expires 2036-02-18 | Direct | 175,000 |
Reported balance
After 2026-02-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-18 · Grant · Acquired 175,000 · Balance 175,000 F1: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001193125-26-059638 · ownership.xml · derivative · entry 1 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2036-02-18 F1 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 23:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0000950170-25-025031 · ownership.xml · derivative · entry 2 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-02-19 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 23:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-025031 · ownership.xml · nonDerivative · entry 1 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,990 F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $17.54 | $0.00 |
DisclosureSEC source: 0000950170-24-019463 · ownership.xml · derivative · entry 2 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-02-22 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-019463 · ownership.xml · nonDerivative · entry 1 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,490 F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years. Read SEC document |
| February 01, 2024 Filed Feb 3, 2024 02:35 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000950170-24-010975 · ownership.xml · derivative · entry 3 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,331 Underlying: Common Stock · 40,000 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on September 1, 2019, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on September 1, 2022. Read SEC document |
| February 01, 2024 Filed Feb 3, 2024 02:35 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 40,000 | $16.18 | $647,200.00 |
DisclosureSEC source: 0000950170-24-010975 · ownership.xml · nonDerivative · entry 2 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,990 F1 · kind: Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.52. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2024 Filed Feb 3, 2024 02:35 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 40,000 | $4.30 | $172,000.00 |
DisclosureSEC source: 0000950170-24-010975 · ownership.xml · nonDerivative · entry 1 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 00:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,003 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000950170-24-009047 · ownership.xml · derivative · entry 4 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,331 Underlying: Common Stock · 26,003 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares vested on September 1, 2019, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on September 1, 2022. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 00:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,997 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000950170-24-009047 · ownership.xml · derivative · entry 3 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,997 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on May 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on May 4, 2023. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 00:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 40,000 | $14.09 | $563,600.00 |
DisclosureSEC source: 0000950170-24-009047 · ownership.xml · nonDerivative · entry 2 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,990 F1 · kind: Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.54. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 00:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 40,000 | $4.30 | $172,000.00 |
DisclosureSEC source: 0000950170-24-009047 · ownership.xml · nonDerivative · entry 1 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,316 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000950170-24-007032 · ownership.xml · derivative · entry 7 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,997 Underlying: Common Stock · 21,316 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares vested on May 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on May 4, 2023. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 21,316 | $12.46 | $265,597.36 |
DisclosureSEC source: 0000950170-24-007032 · ownership.xml · nonDerivative · entry 5 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,990 F1 · kind: Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.16 to $12.60. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 21,316 | $4.30 | $91,658.80 |
DisclosureSEC source: 0000950170-24-007032 · ownership.xml · nonDerivative · entry 4 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,559 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000950170-24-007032 · ownership.xml · derivative · entry 6 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,313 Underlying: Common Stock · 14,559 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares vested on May 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on May 4, 2023. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 4,125 | $12.02 | $49,582.50 |
DisclosureSEC source: 0000950170-24-007032 · ownership.xml · nonDerivative · entry 3 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,990 F1 · kind: Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.09. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 14,559 | $12.18 | $177,328.62 |
DisclosureSEC source: 0000950170-24-007032 · ownership.xml · nonDerivative · entry 2 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,115 F1 · kind: Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.44. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 14,559 | $4.30 | $62,603.70 |
DisclosureSEC source: 0000950170-24-007032 · ownership.xml · nonDerivative · entry 1 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 23:57 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 41,000 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0000899243-23-005735 · doc4.xml · derivative · entry 2 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Stock · 41,000 shares Expires 2033-02-16 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 23:57 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 20,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005735 · doc4.xml · nonDerivative · entry 1 Savill Corrine · CIK 0001837524 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,115 F1 · shares: The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 20:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 14,958 | $15.22 | $227,660.76 |
DisclosureSEC source: 0000899243-22-026470 · doc4.xml · nonDerivative · entry 2 Savill Corrine · CIK 0001837524 · Acting Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,615 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 9, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 18, 2022 Filed Jul 21, 2022 20:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 5,042 | $15.06 | $75,932.52 |
DisclosureSEC source: 0000899243-22-026470 · doc4.xml · nonDerivative · entry 1 Savill Corrine · CIK 0001837524 · Acting Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,573 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 9, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.16. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 11, 2022 Filed Jul 12, 2022 20:14 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 200 | $13.85 | $2,770.00 |
DisclosureSEC source: 0000899243-22-025971 · doc4.xml · nonDerivative · entry 2 Savill Corrine · CIK 0001837524 · Acting Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,615 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 9, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.84 to $13.85. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 11, 2022 Filed Jul 12, 2022 20:14 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 39,800 | $13.33 | $530,534.00 |
DisclosureSEC source: 0000899243-22-025971 · doc4.xml · nonDerivative · entry 1 Savill Corrine · CIK 0001837524 · Acting Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,815 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 9, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.82 to $13.72. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:43 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0000899243-22-006413 · doc4.xml · derivative · entry 2 Savill Corrine · CIK 0001837524 · Acting Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2032-02-10 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:43 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006413 · doc4.xml · nonDerivative · entry 1 Savill Corrine · CIK 0001837524 · Acting Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,615 F1 · shares: The shares underlying the restricted stock unit vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.